INTRODUCTION:Intraarterial thrombolysis and mechanical embolectomy have been studied for endovascular treatment of stroke. The MERCI and Multi MERCI trials of mechanical embolectomy with or without adjuvant intraarterial thrombolysis demonstrated effective recanalization, but with a higher mortality compared with control patients in the PROACT II trial of intraarterial thrombolysis. Differences in trial design may account for this mortality difference. METHODS: We identified patients in the MERCI and Multi MERCI trials who would have been eligible for PROACT II. Rates of good outcome (mRS < or =2) and mortality at 90 days were compared, adjusting for differences in baseline NIHSS score and age. RESULTS:Sixty-eight patients enrolled in MERCI and 81 enrolled in Multi MERCI were eligible for PROACT II. In both unadjusted and adjusted analyses, PROACT II-eligible embolectomy patients showed a trend toward better clinical outcomes compared to the PROACT II control arm (adjusted, MERCI 35.4% [p = ns], Multi MERCI 42.8% [p = 0.048], PROACT II control, 25.4%). In both unadjusted and adjusted analyses, mortality rates did not significantly differ between embolectomy patients and PROACT II control patients (adjusted analysis, MERCI 29.1%, Multi MERCI 18.0%, PROACT II control, 27.1%). Compared with the PROACT II treatment group, embolectomy groups showed similar rates of good outcome and mortality. CONCLUSIONS: Differences in mortality and proportion of good outcome between the MERCI/Multi MERCI trials and the PROACT II trial are explained by differences in study design and baseline characteristics of patients. Mechanical embolectomy and IA thrombolysis may each be reasonable strategies for acute stroke; a randomized trial is necessary to confirm these results.
RCT Entities:
INTRODUCTION:Intraarterial thrombolysis and mechanical embolectomy have been studied for endovascular treatment of stroke. The MERCI and Multi MERCI trials of mechanical embolectomy with or without adjuvant intraarterial thrombolysis demonstrated effective recanalization, but with a higher mortality compared with control patients in the PROACT II trial of intraarterial thrombolysis. Differences in trial design may account for this mortality difference. METHODS: We identified patients in the MERCI and Multi MERCI trials who would have been eligible for PROACT II. Rates of good outcome (mRS < or =2) and mortality at 90 days were compared, adjusting for differences in baseline NIHSS score and age. RESULTS: Sixty-eight patients enrolled in MERCI and 81 enrolled in Multi MERCI were eligible for PROACT II. In both unadjusted and adjusted analyses, PROACT II-eligible embolectomy patients showed a trend toward better clinical outcomes compared to the PROACT II control arm (adjusted, MERCI 35.4% [p = ns], Multi MERCI 42.8% [p = 0.048], PROACT II control, 25.4%). In both unadjusted and adjusted analyses, mortality rates did not significantly differ between embolectomy patients and PROACT II control patients (adjusted analysis, MERCI 29.1%, Multi MERCI 18.0%, PROACT II control, 27.1%). Compared with the PROACT II treatment group, embolectomy groups showed similar rates of good outcome and mortality. CONCLUSIONS: Differences in mortality and proportion of good outcome between the MERCI/Multi MERCI trials and the PROACT II trial are explained by differences in study design and baseline characteristics of patients. Mechanical embolectomy and IA thrombolysis may each be reasonable strategies for acute stroke; a randomized trial is necessary to confirm these results.
Authors: A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera Journal: JAMA Date: 1999-12-01 Impact factor: 56.272
Authors: Wade S Smith; Gene Sung; Sidney Starkman; Jeffrey L Saver; Chelsea S Kidwell; Y Pierre Gobin; Helmi L Lutsep; Gary M Nesbit; Thomas Grobelny; Marilyn M Rymer; Isaac E Silverman; Randall T Higashida; Ronald F Budzik; Michael P Marks Journal: Stroke Date: 2005-06-16 Impact factor: 7.914
Authors: Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Gary A Ford; Martin Grond; Werner Hacke; Michael G Hennerici; Markku Kaste; Sonja Kuelkens; Vincent Larrue; Kennedy R Lees; Risto O Roine; Lauri Soinne; Danilo Toni; Geert Vanhooren Journal: Lancet Date: 2007-01-27 Impact factor: 79.321
Authors: Wade S Smith; Jack W Tsao; Martha E Billings; S Claiborne Johnston; J Claude Hemphill; David C Bonovich; William P Dillon Journal: Neurocrit Care Date: 2006 Impact factor: 3.210
Authors: I Yuki; I Kan; H V Vinters; R H Kim; A Golshan; F A Vinuela; J W Sayre; Y Murayama; F Vinuela Journal: AJNR Am J Neuroradiol Date: 2011-12-29 Impact factor: 3.825
Authors: Liangfu Zhu; David S Liebeskind; Reza Jahan; Sidney Starkman; Noriko Salamon; Gary Duckwiler; Fernando Vinuela; Satoshi Tateshima; Nestor Gonzalez; Pablo Villablanca; Latisha K Ali; Doojin Kim; Bruce Ovbiagele; Michael Froehler; Matthew Tenser; Jeffrey L Saver Journal: Stroke Date: 2012-01-26 Impact factor: 7.914
Authors: Maarten G Lansberg; Martin J O'Donnell; Pooja Khatri; Eddy S Lang; Mai N Nguyen-Huynh; Neil E Schwartz; Frank A Sonnenberg; Sam Schulman; Per Olav Vandvik; Frederick A Spencer; Pablo Alonso-Coello; Gordon H Guyatt; Elie A Akl Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Adnan I Qureshi; Foad Abd-Allah; Aitziber Aleu; John J Connors; Ricardo A Hanel; Ameer E Hassan; Haitham M Hussein; Nazli A Janjua; Rakesh Khatri; Jawad F Kirmani; Mikael Mazighi; Heinrich P Mattle; Jefferson T Miley; Thanh N Nguyen; Gustavo J Rodriguez; Qaisar A Shah; Adnan H Siddiqui; Jose I Suarez; M Fareed K Suri; Reha Tolun Journal: J Vasc Interv Neurol Date: 2014-05
Authors: Saeed Ansari; Maryam Rahman; Douglas J McConnell; Michael F Waters; Brian L Hoh; J Mocco Journal: Neurosurg Rev Date: 2010-11-24 Impact factor: 3.042
Authors: B J Emmer; M Rijkee; J M Niesten; M J H Wermer; B K Velthuis; M A A van Walderveen Journal: Neuroradiology Date: 2014-09-17 Impact factor: 2.804
Authors: E Broussalis; E Trinka; W Hitzl; A Wallner; V Chroust; M Killer-Oberpfalzer Journal: AJNR Am J Neuroradiol Date: 2012-07-12 Impact factor: 3.825